Mallinckrodt Emerges from Chapter 11 with Strengthened Balance Sheet and Enhanced Financial FlexibilityPRNewsWire • 06/16/22
Mallinckrodt Announces Resubmission of Terlipressin to the FDA for the Treatment of Hepatorenal SyndromePRNewsWire • 06/13/22
Mallinckrodt Announces Anticipated Chapter 11 Emergence and Provides Update on Trading of New Ordinary SharesPRNewsWire • 06/13/22
Mallinckrodt Announces Publication of Real-World Data from Retrospective Study on the Investigational Use of Inhaled Nitric Oxide in Hospitalized COVID-19 PatientsPRNewsWire • 04/13/22
Mallinckrodt Earns Top Marks Again in Human Rights Campaign Foundation's 2022 Corporate Equality IndexPRNewsWire • 01/31/22
Mallinckrodt Announces Enrollment of First Patient in Phase 1/2a StrataSOMA Clinical Trial of StrataGraft® (allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen - dsat) for Investigating the Treatment of Full-Thickness BurnsPRNewsWire • 12/16/21
Buxton Helmsley Publicly Responds to Departure of Mallinckrodt Plc. CCO, After Open Letter to U.S. SEC Detailing Accounting FraudBusiness Wire • 11/12/21
Mallinckrodt Presents Results from Two Retrospective Studies on Real World Characteristics and Outcomes of Patients with Hepatorenal Syndrome Type-1 (HRS-1) at The Liver Meeting Digital ExperiencePRNewsWire • 11/12/21
Buxton Helmsley Publicly Responds to Resignation of Mallinckrodt Plc. SVP, Finance, Days After Open Letter to U.S. SEC Detailing Accounting FraudBusiness Wire • 11/05/21
The Buxton Helmsley Group Calls on U.S. Securities and Exchange Commission to Intervene in Mallinckrodt Plc. Fraud Involving False Statements of Financials, Insider Trading on Undisclosed Information, and Electoral TamperingBusiness Wire • 10/26/21
Mallinckrodt Presents Results on Real World Treatment Patterns and Outcomes in Hospitalized Patients with Esophageal Variceal Hemorrhage and Liver Cirrhosis Treated with Terlipressin at the American College of Gastroenterology Annual Scientific MeetingPRNewsWire • 10/25/21
Mallinckrodt Reaches Settlements with the Official Committee of Opioid Related Creditors, the Official Committee of Unsecured Creditors and Second Lien NoteholdersPRNewsWire • 09/03/21
Mallinckrodt Announces Inclusion of Acthar® Gel (Repository Corticotropin Injection) in New European Respiratory Society (ERS) Treatment Guidelines for Patients with Pulmonary SarcoidosisPRNewsWire • 07/01/21
Mallinckrodt Announces U.S. FDA Approval of StrataGraft® (allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen - dsat)PRNewsWire • 06/15/21
Mallinckrodt Presents Data Evaluating Acthar® Gel (Repository Corticotropin Injection) for the Treatment of Severe Keratitis at the Association for Research in Vision and Ophthalmology (ARVO) Annual MeetingPRNewsWire • 05/03/21
Mallinckrodt Presents Data Evaluating INOmax® (Nitric Oxide) Gas, for Inhalation in a Phase 4 Observational Registry in Neonates with Pulmonary Hypertension at the Pediatric Academic Societies (PAS) 2021 Virtual MeetingPRNewsWire • 04/30/21
National Association of Manufacturers Selects Mallinckrodt for Two Prestigious Manufacturing Leadership AwardsPRNewsWire • 03/29/21
Mallinckrodt Gains Support for Its Restructuring Support Agreement from Lenders Holding Approximately $1.3 Billion of Its First Lien Term LoansPRNewsWire • 03/10/21
Mallinckrodt Announces New England Journal of Medicine Publication of Results from its Phase 3 CONFIRM Study of Terlipressin in Patients with Hepatorenal Syndrome Type 1 (HRS-1)PRNewsWire • 03/04/21
